IUPHAR/BPS Guide to Pharmacology CITE

Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Corinne Bosquet1, Justo P. Castaño2, Zsolt Csaba3, Micheal Culler4, Pascal Dournaud3, Jacques Epelbaum5, Wasyl Feniuk6, Anthony Harmar7, Rebecca Hills7, Leo Hofland8, Daniel Hoyer9, Patrick P. A. Humphrey6, Hans-Jürgen Kreienkamp10, Amelie Lupp11, Shlomo Melmed12, Wolfgang Meyerhof13, Anne-Marie O'Carroll14, Yogesh C. Patel15, Terry Reisine16, Jean-Claude Reubi17, Marcus Schindler18, Herbert Schmid19, Agnes Schonbrunn20, Stefan Schulz21, John E. Taylor22, Giovanni Tulipano23, Annamaria Vezzani24 and Hans-Jürgen Wester25
  1. University Toulouse III Paul Sabatier, France
  2. University of Cordoba, Spain
  3. Université Paris Diderot, France
  4. Ipsen, USA
  6. University of Cambridge, UK
  7. University of Edinburgh, UK
  8. Erasmus Medical Center, The Netherlands
  9. University of Melbourne, Australia
  10. University Medical Center Hamburg-Eppendorf, Germany
  11. Friedrich-Schiller-University, Germany
  12. Cedars-Sinai Medical Center, USA
  13. Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke, Germany
  14. University of Bristol, UK
  15. McGill University, Canada
  16. ActiveSite Biotech, USA
  17. University of Berne, Switzerland
  18. Boehringer Ingelheim Pharma, Germany
  19. Novartis Institutes for Biomedical Research, Switzerland
  20. University of Texas, USA
  21. Friedrich Schiller University, Germany
  22. Biomeasure Inc, USA
  23. University of Brescia, Italy
  24. Istituto di Ricerche Farmacologiche Mario Negri, Italy
  25. Technische Universität München, Germany


Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin receptor (SST1-SST5; nomenclature as agreed by the NC-IUPHAR Subcommittee on Somatostatin Receptors [89]). Activation of these receptors produces a wide range of physiological effects throughout the body including the inhibition of secretion of many hormones. Endogenous ligands for these receptors are somatostatin-14 (SRIF-14) and somatostatin-28 (SRIF-28). cortistatin-14 has also been suggested to be an endogenous ligand for somatostatin receptors [56].


This is a citation summary for Somatostatin receptors in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts.

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

Somatostatin receptors
Introduction to Somatostatin receptors
            SST1 receptor
            SST2 receptor
            SST3 receptor
            SST4 receptor
            SST5 receptor


  1. (1988) Bombesin-like peptides in health and disease. Proceedings of an international symposium. October 13-16, 1987, Rome, Italy. A tribute to Vittorio Erspamer, M.D. Ann. N. Y. Acad. Sci. 547: 1-541 [PMID:3071214]
  2. Abdu F, Hicks GA, Hennig G, Allen JP and Grundy D. (2002) Somatostatin sst(2) receptors inhibit peristalsis in the rat and mouse jejunum. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G624-33 [PMID:11897621]
  3. Acunzo J, Thirion S, Roche C, Saveanu A, Gunz G, Germanetti AL, Couderc B, Cohen R, Figarella-Branger D and Dufour H et al.. (2008) Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res. 68: 10163-70 [PMID:19074883]
  4. Adams RL, Adams IP, Lindow SW and Atkin SL. (2004) Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clin. Endocrinol. (Oxf) 61: 431-6 [PMID:15473874]
  5. Adams RL, Adams IP, Lindow SW, Zhong W and Atkin SL. (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br. J. Cancer 92: 1493-8 [PMID:15812556]
  6. Akbar M, Okajima F, Tomura H, Majid MA, Yamada Y, Seino S and Kondo Y. (1994) Phospholipase C activation and Ca2+ mobilization by cloned human somatostatin receptor subtypes 1-5, in transfected COS-7 cells. FEBS Lett. 348: 192-6 [PMID:8034040]
  7. Albini A, Florio T, Giunciuglio D, Masiello L, Carlone S, Corsaro A, Thellung S, Cai T, Noonan DM and Schettini G. (1999) Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J. 13: 647-55 [PMID:10094925]
  8. Allen JP, Canty AJ, Schulz S, Humphrey PP, Emson PC and Young HM. (2002) Identification of cells expressing somatostatin receptor 2 in the gastrointestinal tract of Sstr2 knockout/lacZ knockin mice. J. Comp. Neurol. 454: 329-40 [PMID:12442323]
  9. Allen JP, Hathway GJ, Clarke NJ, Jowett MI, Topps S, Kendrick KM, Humphrey PP, Wilkinson LS and Emson PC. (2003) Somatostatin receptor 2 knockout/lacZ knockin mice show impaired motor coordination and reveal sites of somatostatin action within the striatum. Eur. J. Neurosci. 17: 1881-95 [PMID:12752788]
  10. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC and Maecke H. (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur. J. Nucl. Med. Mol. Imaging 34: 982-93 [PMID:17225119]
  11. Arena S, Pattarozzi A, Corsaro A, Schettini G and Florio T. (2005) Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. Mol. Endocrinol. 19: 255-67 [PMID:15388796]
  12. Armani C, Catalani E, Balbarini A, Bagnoli P and Cervia D. (2007) Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J. Leukoc. Biol. 81: 845-55 [PMID:17148691]
  13. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R and Buscail L. (2008) Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J. Clin. Oncol. 26: 963-70 [PMID:18281671]
  14. Azar R, Najib S, Lahlou H, Susini C and Pyronnet S. (2008) Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1. Cell. Mol. Life Sci. 65: 3110-7 [PMID:18810319]
  15. Ballarè E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P and Faglia G et al.. (2001) Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J. Clin. Endocrinol. Metab. 86: 3809-14 [PMID:11502816]
  16. Barbieri F, Pattarozzi A, Gatti M, Aiello C, Quintero A, Lunardi G, Bajetto A, Ferrari A, Culler MD and Florio T. (2009) Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am. J. Physiol. Endocrinol. Metab. 297: E1078-88 [PMID:19706788]
  17. Barbieri F, Pattarozzi A, Gatti M, Porcile C, Bajetto A, Ferrari A, Culler MD and Florio T. (2008) Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2. Endocrinology 149: 4736-46 [PMID:18566118]
  18. Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J and Hadcock JR. (1996) Identification and characterization of novel somatostatin antagonists. Mol. Pharmacol. 50: 709-15 [PMID:8863814]
  19. Baumbach WR, Carrick TA, Pausch MH, Bingham B, Carmignac D, Robinson IC, Houghten R, Eppler CM, Price LA and Zysk JR. (1998) A linear hexapeptide somatostatin antagonist blocks somatostatin activity in vitro and influences growth hormone release in rats. Mol. Pharmacol. 54: 864-73 [PMID:9804621]
  20. Baumeister H, Kreuzer OJ, Roosterman D, Schäfer J and Meyerhof W. (1998) Cloning, expression, pharmacology and tissue distribution of the mouse somatostatin receptor subtype 5. J. Neuroendocrinol. 10: 283-90 [PMID:9630398]
  21. Beaudet A, Greenspun D, Raelson J and Tannenbaum GS. (1995) Patterns of expression of SSTR1 and SSTR2 somatostatin receptor subtypes in the hypothalamus of the adult rat: relationship to neuroendocrine function. Neuroscience 65: 551-61 [PMID:7777168]
  22. Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, Esteve JP, Pour PM, Schally AV and Vaysse N et al.. (2000) Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc. Natl. Acad. Sci. U.S.A. 97: 9180-5 [PMID:10900262]
  23. Beneyto M, Morris HM, Rovensky KC and Lewis DA. (2012) Lamina- and cell-specific alterations in cortical somatostatin receptor 2 mRNA expression in schizophrenia. Neuropharmacology 62: 1598-605 [PMID:21215273]
  24. Bigiani A, Petrucci C, Ghiaroni V, Dal Monte M, Cozzi A, Kreienkamp HJ, Richter D and Bagnoli P. (2004) Functional correlates of somatostatin receptor 2 overexpression in the retina of mice with genetic deletion of somatostatin receptor 1. Brain Res. 1025: 177-85 [PMID:15464758]
  25. Bito H, Mori M, Sakanaka C, Takano T, Honda Z, Gotoh Y, Nishida E and Shimizu T. (1994) Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade. J. Biol. Chem. 269: 12722-30 [PMID:8175684]
  26. Bousquet C, Guillermet-Guibert J, Saint-Laurent N, Archer-Lahlou E, Lopez F, Fanjul M, Ferrand A, Fourmy D, Pichereaux C and Monsarrat B et al.. (2006) Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J. 25: 3943-54 [PMID:16917505]
  27. Breder CD, Yamada Y, Yasuda K, Seino S, Saper CB and Bell GI. (1992) Differential expression of somatostatin receptor subtypes in brain. J. Neurosci. 12: 3920-34 [PMID:1403090]
  28. Brinkmeier ML, Stahl JH, Gordon DF, Ross BD, Sarapura VD, Dowding JM, Kendall SK, Lloyd RV, Ridgway EC and Camper SA. (2001) Thyroid hormone-responsive pituitary hyperplasia independent of somatostatin receptor 2. Mol. Endocrinol. 15: 2129-36 [PMID:11731614]
  29. Bruno JF, Xu Y, Song J and Berelowitz M. (1992) Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc. Natl. Acad. Sci. U.S.A. 89: 11151-5 [PMID:1360663]
  30. Bruno JF, Xu Y, Song J and Berelowitz M. (1993) Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology 133: 2561-7 [PMID:8243278]
  31. Bruns C, Raulf F, Hoyer D, Schloos J, Lübbert H and Weckbecker G. (1996) Binding properties of somatostatin receptor subtypes. Metab. Clin. Exp. 45: 17-20 [PMID:8769372]
  32. Buscail L, Delesque N, Estève JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C and Schally AV et al.. (1994) Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc. Natl. Acad. Sci. U.S.A. 91: 2315-9 [PMID:7907795]
  33. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N and Susini C. (1996) Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 56: 1823-7 [PMID:8620499]
  34. Cardoso A, el Ghamrawy C, Gautron JP, Horvat B, Gautier N, Enjalbert A and Krantic S. (1998) Somatostatin increases mitogen-induced IL-2 secretion and proliferation of human Jurkat T cells via sst3 receptor isotype. J. Cell. Biochem. 68: 62-73 [PMID:9407314]
  35. Caron P, Buscail L, Beckers A, Estève JP, Igout A, Hennen G and Susini C. (1997) Expression of somatostatin receptor SST4 in human placenta and absence of octreotide effect on human placental growth hormone concentration during pregnancy. J. Clin. Endocrinol. Metab. 82: 3771-6 [PMID:9360539]
  36. Carrere N, Vernejoul F, Souque A, Asnacios A, Vaysse N, Pradayrol L, Susini C, Buscail L and Cordelier P. (2005) Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum. Gene Ther. 16: 1175-93 [PMID:16218779]
  37. Carruthers AM, Warner AJ, Michel AD, Feniuk W and Humphrey PP. (1999) Activation of adenylate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of Galphas proteins. Br. J. Pharmacol. 126: 1221-9 [PMID:10205012]
  38. Casini G, Dal Monte M, Petrucci C, Gambellini G, Grouselle D, Allen JP, Kreienkamp HJ, Richter D, Epelbaum J and Bagnoli P. (2004) Altered morphology of rod bipolar cell axonal terminals in the retinas of mice carrying genetic deletion of somatostatin subtype receptor 1 or 2. Eur. J. Neurosci. 19: 43-54 [PMID:14750962]
  39. Castro SW, Buell G, Feniuk W and Humphrey PP. (1996) Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1 and sst2, in mouse fibroblast (Ltk-) cells. Br. J. Pharmacol. 117: 639-46 [PMID:8646408]
  40. Cattaneo MG, Amoroso D, Gussoni G, Sanguini AM and Vicentini LM. (1996) A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines. FEBS Lett 397: 164-168 [PMID:8955339]
  41. Cejvan K, Coy DH and Efendic S. (2003) Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes 52: 1176-81 [PMID:12716749]
  42. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK and Theodoropoulou M. (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res. 70: 666-74 [PMID:20068168]
  43. Cervia D, Zizzari P, Pavan B, Schuepbach E, Langenegger D, Hoyer D, Biondi C, Epelbaum J and Bagnoli P. (2003) Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1-sst5 receptor-selective nonpeptidyl agonists. Neuropharmacology 44: 672-85 [PMID:12668053]
  44. Cescato R, Erchegyi J, Waser B, Piccand V, Maecke HR, Rivier JE and Reubi JC. (2008) Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J. Med. Chem. 51: 4030-7 [PMID:18543899]
  45. Cescato R, Loesch KA, Waser B, Mäcke HR, Rivier JE, Reubi JC and Schonbrunn A. (2010) Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol. Endocrinol. 24: 240-9 [PMID:19910453]
  46. Chen L and Tashjian Jr AH. (1999) Identification of distinct signalling pathways for somatostatin receptors SSTR1 and SSTR2 as revealed by microphysiometry. Cell. Signal. 11: 499-505 [PMID:10405760]
  47. Cheng H, Grodnitzky JA, Yibchok-anun S, Ding J and Hsu WH. (2005) Somatostatin increases phospholipase D activity and phosphatidylinositol 4,5-bisphosphate synthesis in clonal beta cells HIT-T15. Mol. Pharmacol. 67: 2162-72 [PMID:15784846]
  48. Colao A, Faggiano A and Pivonello R. (2010) Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. Prog. Brain Res. 182: 281-94 [PMID:20541670]
  49. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR and Biller BM et al.. (2012) A 12-month phase 3 study of pasireotide in Cushing's disease. N. Engl. J. Med. 366: 914-24 [PMID:22397653]
  50. Cordelier P, Estève JP, Bousquet C, Delesque N, O'Carroll AM, Schally AV, Vaysse N, Susini C and Buscail L. (1997) Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc. Natl. Acad. Sci. U.S.A. 94: 9343-8 [PMID:9256484]
  51. Corness JD, Demchyshyn LL, Seeman P, Van Tol HH, Srikant CB, Kent G, Patel YC and Niznik HB. (1993) A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett. 321: 279-84 [PMID:8097479]
  52. Curtis SB, Hewitt J, Yakubovitz S, Anzarut A, Hsiang YN and Buchan AM. (2000) Somatostatin receptor subtype expression and function in human vascular tissue. Am. J. Physiol. Heart Circ. Physiol. 278: H1815-22 [PMID:10843877]
  53. Dal Monte M, Cammalleri M, Martini D, Casini G and Bagnoli P. (2007) Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest. Ophthalmol. Vis. Sci. 48: 3480-9 [PMID:17652715]
  54. Dasgupta P. (2004) Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol. Ther. 102: 61-85 [PMID:15056499]
  55. Day R, Dong W, Panetta R, Kraicer J, Greenwood MT and Patel YC. (1995) Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology 136: 5232-5 [PMID:7588263]
  56. de Lecea L, Criado JR, Prospero-Garcia O, Gautvik KM, Schweitzer P, Danielson PE, Dunlop CL, Siggins GR, Henriksen SJ and Sutcliffe JG. (1996) A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 381: 242-5 [PMID:8622767]
  57. de Lecea L, Ruiz-Lozano P, Danielson PE, Peelle-Kirley J, Foye PE, Frankel WN and Sutcliffe JG. (1997) Cloning, mRNA expression, and chromosomal mapping of mouse and human preprocortistatin. Genomics 42: 499-506 [PMID:9205124]
  58. Delesque N, Buscail L, Estève JP, Saint-Laurent N, Müller C, Weckbecker G, Bruns C, Vaysse N and Susini C. (1997) sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 57: 956-62 [PMID:9041201]
  59. Demchyshyn LL, Srikant CB, Sunahara RK, Kent G, Seeman P, Van Tol HH, Panetta R, Patel YC and Niznik HB. (1993) Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol. Pharmacol. 43: 894-901 [PMID:8100352]
  60. Dent P, Wang Y, Gu YZ, Wood SL, Reardon DB, Mangues R, Pellicer A, Schonbrunn A and Sturgill TW. (1997) S49 cells endogenously express subtype 2 somatostatin receptors which couple to increase protein tyrosine phosphatase activity in membranes and down-regulate Raf-1 activity in situ. Cell. Signal. 9: 539-49 [PMID:9419818]
  61. Denzler B and Reubi JC. (1999) Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 85: 188-98 [PMID:9921992]
  62. Dournaud P, Gu YZ, Schonbrunn A, Mazella J, Tannenbaum GS and Beaudet A. (1996) Localization of the somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody. J. Neurosci. 16: 4468-78 [PMID:8699257]
  63. Durán-Prado M, Gahete MD, Martínez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-López P, Leal A, Schulz S and Gracia-Navarro F et al.. (2009) Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J. Clin. Endocrinol. Metab. 94: 2634-43 [PMID:19401364]
  64. Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, Reubi JC and Mäcke HR. (2002) NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug. Chem. 13: 530-41 [PMID:12009943]
  65. Elberg G, Hipkin RW and Schonbrunn A. (2002) Homologous and heterologous regulation of somatostatin receptor 2. Mol. Endocrinol. 16: 2502-14 [PMID:12403839]
  66. Engström M, Tomperi J, El-Darwish K, Ahman M, Savola JM and Wurster S. (2005) Superagonism at the human somatostatin receptor subtype 4. J. Pharmacol. Exp. Ther. 312: 332-8 [PMID:15333679]
  67. Epelbaum J, Briard N, Djordjijevic D, Dutour A, Meyerhoff W, Oliver C, Slama A, Viollet C and Zhang J. (1998) Characterization of somatostatin receptor subtypes in mammalian pituitary. Ann N Y Acad Sci 839: 249-253 [PMID:9629161]
  68. Erchegyi J, Hoeger CA, Low W, Hoyer D, Waser B, Eltschinger V, Schaer JC, Cescato R, Reubi JC and Rivier JE. (2005) Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem 48: 507-514 [PMID:15658864]
  69. Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, Waser B, Weber WA, Reubi JC and Maecke HR. (2011) PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J. Nucl. Med. 52: 1110-8 [PMID:21680701]
  70. Fani M, Mueller A, Tamma ML, Nicolas G, Rink HR, Cescato R, Reubi JC and Maecke HR. (2010) Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. J. Nucl. Med. 51: 1771-9 [PMID:20956465]
  71. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L and Susini C. (2000) Signal transduction of somatostatin receptors negatively controlling cell proliferation. J. Physiol. Paris 94: 205-10 [PMID:11087998]
  72. Ferjoux G, Lopez F, Esteve JP, Ferrand A, Vivier E, Vely F, Saint-Laurent N, Pradayrol L, Buscail L and Susini C. (2003) Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol. Biol. Cell 14: 3911-28 [PMID:12972574]
  73. Ferone D, Pivonello R, Kwekkeboom DJ, Gatto F, Ameri P, Colao A, de Krijger RR, Minuto F, Lamberts SW and van Hagen PM et al.. (2012) Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy. J. Endocrinol. Invest. 35: 528-34 [PMID:21765239]
  74. Ferone D, Pivonello R, Van Hagen PM, Dalm VA, Lichtenauer-Kaligis EG, Waaijers M, Van Koetsveld PM, Mooy DM, Colao A and Minuto F et al.. (2002) Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am. J. Physiol. Endocrinol. Metab. 283: E1056-66 [PMID:12376335]
  75. Feuerbach D, Fehlmann D, Nunn C, Siehler S, Langenegger D, Bouhelal R, Seuwen K and Hoyer D. (2000) Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor. Neuropharmacology 39: 1451-62 [PMID:10818261]
  76. Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M and Culler MD et al.. (2008) Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr. Relat. Cancer 15: 583-96 [PMID:18509006]
  77. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM and Schettini G et al.. (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144: 1574-84 [PMID:12639942]
  78. Florio T, Rim C, Hershberger RE, Loda M and Stork PJ. (1994) The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Mol. Endocrinol. 8: 1289-97 [PMID:7854346]
  79. Florio T, Scorizello A, Fattore M, D'Alto V, Salzano S, Rossi G, Berlingieri MT, Fusco A and Schettini G. (1996) Somatostatin inhibits PC Cl3 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene. J. Biol. Chem. 271: 6129-36 [PMID:8626400]
  80. Florio T, Yao H, Carey KD, Dillon TJ and Stork PJ. (1999) Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 13: 24-37 [PMID:9892010]
  81. Ghosh M and Schonbrunn A. (2011) Differential temporal and spatial regulation of somatostatin receptor phosphorylation and dephosphorylation. J. Biol. Chem. 286: 13561-73 [PMID:21343287]
  82. Gillies G. (1997) Somatostatin: the neuroendocrine story. Trends Pharmacol. Sci. 18: 87-95 [PMID:9133778]
  83. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC and Maecke HR. (2005) Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin. Cancer Res. 11: 1136-45 [PMID:15709181]
  84. Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H, Cescato R, Reubi JC and Maecke HR. (2008) New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin. Cancer Res. 14: 2019-27 [PMID:18381940]
  85. Gong AY, Tietz PS, Muff MA, Splinter PL, Huebert RC, Strowski MZ, Chen XM and LaRusso NF. (2003) Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am. J. Physiol., Cell Physiol. 284: C1205-14 [PMID:12676656]
  86. Gordon DF, Woodmansee WW, Lewis SR, James RA, Wood WM and Ridgway EC. (1999) Cloning of the mouse somatostatin receptor subtype 5 gene: promoter structure and function. Endocrinology 140: 5598-608 [PMID:10579323]
  87. Gugger M, Waser B, Kappeler A, Schonbrunn A and Reubi JC. (2004) Cellular detection of sst2A receptors in human gastrointestinal tissue. Gut 53: 1431-1436 [PMID:15361490]
  88. Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, Pradayrol L, Buscail L, Susini C and Bousquet C. (2003) Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 100: 155-60 [PMID:12490654]
  89. Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP and Wester HJ et al.. (2018) International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol. Rev. 70: 763-835 [PMID:30232095]
  90. Hagemeister AL, Kittilson JD, Bergan HE and Sheridan MA. (2010) Rainbow trout somatostatin receptor subtypes SSTR1A, SSTR1B, and SSTR2 differentially activate the extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling pathways in transfected cells. J. Mol. Endocrinol. 45: 317-27 [PMID:20732992]
  91. Held-Feindt J, Forstreuter F, Pufe T and Mentlein R. (2001) Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Brain Res. Mol. Brain Res. 87: 12-21 [PMID:11223155]
  92. Hervieu G and Emson PC. (1999) Visualisation of somatostatin receptor sst(3) in the rat central nervous system. Brain Res. Mol. Brain Res. 71: 290-303 [PMID:10521583]
  93. Hipkin RW, Friedman J, Clark RB, Eppler CM and Schonbrunn A. (1997) Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J. Biol. Chem. 272: 13869-76 [PMID:9153246]
  94. Ho MK, Yung LY, Chan JS, Chan JH, Wong CS and Wong YH. (2001) Galpha(14) links a variety of G(i)- and G(s)-coupled receptors to the stimulation of phospholipase C. Br. J. Pharmacol. 132: 1431-40 [PMID:11264236]
  95. Hocart SJ, Jain R, Murphy WA, Taylor JE and Coy DH. (1999) Highly potent cyclic disulfide antagonists of somatostatin. J. Med. Chem. 42: 1863-71 [PMID:10354394]
  96. Hocart SJ, Jain R, Murphy WA, Taylor JE, Morgan B and Coy DH. (1998) Potent antagonists of somatostatin: synthesis and biology. J. Med. Chem. 41: 1146-54 [PMID:9544214]
  97. Holloway S, Feniuk W, Kidd EJ and Humphrey PP. (1996) A quantitative autoradiographical study on the distribution of somatostatin sst2 receptors in the rat central nervous system using [125I]-BIM-23027. Neuropharmacology 35: 1109-20 [PMID:9121614]
  98. Hou C, Gilbert RL and Barber DL. (1994) Subtype-specific signaling mechanisms of somatostatin receptors SSTR1 and SSTR2. J. Biol. Chem. 269: 10357-62 [PMID:8144617]
  99. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O'Carroll AM, Patel YC, Schonbrunn A and Taylor JE et al.. (1995) Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 16: 86-8 [PMID:7792934]
  100. Hoyer D, Epelbaum J, Feniuk W, Humphrey PPA, Meyerhof W and O'Carroll AM et al.. (2000) Somatostatin receptors. In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd edn. Edited by Watson SP, Girdlestone D: IUPHAR Media: 354-364
  101. Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, Langenegger D, Bouhelal R, Hurth K and Neumann P et al.. (2004) SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. Neurosci. Lett. 361: 132-5 [PMID:15135911]
  102. Hoyer D, Vassout A, Gentsch C, Enz A, Vigouret JM, Jaton A, Schoeffter P, Kelly P, Wrynn A, Hurth K and Troxler T. (2004) Functional characterization of NVP ACQ090, a somatostatin sst3 receptor antagonist. Soc Neuroscience Abs -
  103. Hunyady B, Hipkin RW, Schonbrunn A and Mezey E. (1997) Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas. Endocrinology 138: 2632-5 [PMID:9165058]
  104. Händel M, Schulz S, Stanarius A, Schreff M, Erdtmann-Vourliotis M, Schmidt H, Wolf G and Höllt V. (1999) Selective targeting of somatostatin receptor 3 to neuronal cilia. Neuroscience 89: 909-26 [PMID:10199624]
  105. Kaemmerer D, Lupp A, Peter L, Fischer E, Schulz S, Klöppel G and Hommann M. (2013) Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors. Int J Clin Exp Pathol 6: 49-54 [PMID:23236542]
  106. Kao YJ, Ghosh M and Schonbrunn A. (2011) Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol. Endocrinol. 25: 1040-54 [PMID:21493671]
  107. Kaupmann K, Bruns C, Hoyer D, Seuwen K and Lubbert H. (1993) Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain. FEBS Lett 331: 53-59 [PMID:8405411]
  108. Khare S, Kumar U, Sasi R, Puebla L, Calderon L, Lemstrom K, Hayry P and Patel AY. (1999) Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty. FASEB J. 13: 387-94 [PMID:9973327]
  109. Kluxen FW, Bruns C and Lübbert H. (1992) Expression cloning of a rat brain somatostatin receptor cDNA. Proc. Natl. Acad. Sci. U.S.A. 89: 4618-22 [PMID:1374909]
  110. Komasaka M, Horie S, Watanabe K and Murayama T. (2002) Antisecretory effect of somatostatin on gastric acid via inhibition of histamine release in isolated mouse stomach. Eur. J. Pharmacol. 452: 235-43 [PMID:12354575]
  111. Kreienkamp HJ, Akgün E, Baumeister H, Meyerhof W and Richter D. (1999) Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs. FEBS Lett. 462: 464-6 [PMID:10622746]
  112. Kreienkamp HJ, Hönck HH and Richter D. (1997) Coupling of rat somatostatin receptor subtypes to a G-protein gated inwardly rectifying potassium channel (GIRK1). FEBS Lett. 419: 92-4 [PMID:9426226]
  113. Kreuzer OJ, Krisch B, Déry O, Bunnett NW and Meyerhof W. (2001) Agonist-mediated endocytosis of rat somatostatin receptor subtype 3 involves beta-arrestin and clathrin coated vesicles. J. Neuroendocrinol. 13: 279-87 [PMID:11207943]
  114. Krulich L, Dhariwal AP and McCann SM. (1968) Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83: 783-90 [PMID:4879544]
  115. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC and Patel YC. (1999) Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48: 77-85 [PMID:9892225]
  116. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C and Susini C. (2004) Molecular signaling of somatostatin receptors. Ann. N. Y. Acad. Sci. 1014: 121-31 [PMID:15153426]
  117. Lahlou H, Saint-Laurent N, Estève JP, Eychène A, Pradayrol L, Pyronnet S and Susini C. (2003) sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J. Biol. Chem. 278: 39356-71 [PMID:12878607]
  118. Laklai H, Laval S, Dumartin L, Rochaix P, Hagedorn M, Bikfalvi A, Le Guellec S, Delisle MB, Schally AV and Susini C et al.. (2009) Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc. Natl. Acad. Sci. U.S.A. 106: 17769-74 [PMID:19805200]
  119. Lanneau C, Viollet C, Faivre-Bauman A, Loudes C, Kordon C, Epelbaum J and Gardette R. (1998) Somatostatin receptor subtypes sst1 and sst2 elicit opposite effects on the response to glutamate of mouse hypothalamic neurones: an electrophysiological and single cell RT-PCR study. Eur. J. Neurosci. 10: 204-12 [PMID:9753128]
  120. Lattuada D, Casnici C, Crotta K, Mastrotto C, Franco P, Schmid HA and Marelli O. (2007) Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J. Neuroimmunol. 182: 153-9 [PMID:17113654]
  121. Law SF, Manning D and Reisine T. (1991) Identification of the subunits of GTP-binding proteins coupled to somatostatin receptors. J Biol Chem 266: 17885-17897 [PMID:1655730]
  122. Law SF, Woulfe D and Reisine T. (1995) Somatostatin receptor activation of cellular effector systems. Cell. Signal. 7: 1-8 [PMID:7538774]
  123. Le Romancer M, Cherifi Y, Levasseur S, Laigneau JP, Peranzi G, Jais P, Lewin MJ and Reyl-Desmars F. (1996) Messenger RNA expression of somatostatin receptor subtypes in human and rat gastric mucosae. Life Sci. 58: 1091-8 [PMID:8622562]
  124. Le Verche V, Kaindl AM, Verney C, Csaba Z, Peineau S, Olivier P, Adle-Biassette H, Leterrier C, Vitalis T and Renaud J et al.. (2009) The somatostatin 2A receptor is enriched in migrating neurons during rat and human brain development and stimulates migration and axonal outgrowth. PLoS ONE 4: e5509 [PMID:19434240]
  125. Lepousez G, Mouret A, Loudes C, Epelbaum J and Viollet C. (2010) Somatostatin contributes to in vivo gamma oscillation modulation and odor discrimination in the olfactory bulb. J. Neurosci. 30: 870-5 [PMID:20089895]
  126. Lesche S, Lehmann D, Nagel F, Schmid HA and Schulz S. (2009) Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metab. 94: 654-61 [PMID:19001514]
  127. Li XJ, Forte M, North RA, Ross CA and Snyder SH. (1992) Cloning and expression of a rat somatostatin receptor enriched in brain. J. Biol. Chem. 267: 21307-12 [PMID:1400442]
  128. Liapakis G, Tallent M and Reisine T. (1996) Molecular and functional properties of somatostain receptor subtypes. Metab. Clin. Exp. 45: 12-3 [PMID:8769370]
  129. Liew CW, Vockel M, Glassmeier G, Brandner JM, Fernandez-Ballester GJ, Schwarz JR, Schulz S, Buck F, Serrano L and Richter D et al.. (2009) Interaction of the human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables somatostatin to control permeability of epithelial tight junctions. FEBS Lett. 583: 49-54 [PMID:19071123]
  130. Lin CY, Varma MG, Joubel A, Madabushi S, Lichtarge O and Barber DL. (2003) Conserved motifs in somatostatin, D2-dopamine, and alpha 2B-adrenergic receptors for inhibiting the Na-H exchanger, NHE1. J. Biol. Chem. 278: 15128-35 [PMID:12566440]
  131. Liu AM and Wong YH. (2005) Activation of nuclear factor {kappa}B by somatostatin type 2 receptor in pancreatic acinar AR42J cells involves G{alpha}14 and multiple signaling components: a mechanism requiring protein kinase C, calmodulin-dependent kinase II, ERK, and c-Src. J. Biol. Chem. 280: 34617-25 [PMID:16115892]
  132. Liu Q, Bee MS and Schonbrunn A. (2009) Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (Sst2A) phosphorylation. Mol. Pharmacol. 76: 68-80 [PMID:19389921]
  133. Liu Q, Cescato R, Dewi DA, Rivier J, Reubi JC and Schonbrunn A. (2005) Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol. Pharmacol. 68: 90-101 [PMID:15855408]
  134. Liu Q, Reubi JC, Wang Y, Knoll BJ and Schonbrunn A. (2003) In vivo phosphorylation of the somatostatin 2A receptor in human tumors. J. Clin. Endocrinol. Metab. 88: 6073-9 [PMID:14671213]
  135. Liu S, Tang C, Ho B, Ankersen M, Stidsen CE and Crider AM. (1998) Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas. J. Med. Chem. 41: 4693-705 [PMID:9822540]
  136. Low MJ. (2004) Clinical endocrinology and metabolism. The somatostatin neuroendocrine system: physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Pract. Res. Clin. Endocrinol. Metab. 18: 607-22 [PMID:15533778]
  137. Lublin AL, Diehl NL and Hochgeschwender U. (1997) Isolation and characterization of the gene encoding the type 5 mouse (Mus musculus) somatostatin receptor (msst5). Gene 195: 63-6 [PMID:9300821]
  138. Lupp A, Nagel F, Doll C, Röcken C, Evert M, Mawrin C, Saeger W and Schulz S. (2012) Reassessment of sst3 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-5. Neuroendocrinology 96: 301-10 [PMID:22414742]
  139. Maecke HR and Reubi JC. (2011) Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J. Nucl. Med. 52: 841-4 [PMID:21571797]
  140. Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WA, van Gameren A, van den Berg R, Reubi JC, Krenning EP and de Jong M. (2006) [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate. Eur. J. Nucl. Med. Mol. Imaging 33: 831-40 [PMID:16568203]
  141. Martinez V, Curi AP, Torkian B, Schaeffer JM, Wilkinson HA, Walsh JH and Taché Y. (1998) High basal gastric acid secretion in somatostatin receptor subtype 2 knockout mice. Gastroenterology 114: 1125-32 [PMID:9609748]
  142. Martínez V, Coy DH, Lloyd KC and Taché Y. (1996) Intracerebroventricular injection of somatostatin sst5 receptor agonist inhibits gastric acid secretion in rats. Eur. J. Pharmacol. 296: 153-60 [PMID:8838451]
  143. Mastrodimou N and Thermos K. (2004) The somatostatin receptor (sst1) modulates the release of somatostatin in rat retina. Neurosci. Lett. 356: 13-6 [PMID:14746890]
  144. Maurer R and Reubi JC. (1986) Somatostatin receptors in the adrenal. Mol. Cell. Endocrinol. 45: 81-90 [PMID:3009249]
  145. Meyerhof W. (1998) The elucidation of somatostatin receptor functions: a current view. Rev. Physiol. Biochem. Pharmacol. 133: 55-108 [PMID:9600011]
  146. Meyerhof W, Wulfsen I, Schönrock C, Fehr S and Richter D. (1992) Molecular cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain. Proc. Natl. Acad. Sci. U.S.A. 89: 10267-71 [PMID:1279674]
  147. Mezey E, Hunyady B, Mitra S, Hayes E, Liu Q, Schaeffer J and Schonbrunn A. (1998) Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology 139: 414-9 [PMID:9421441]
  148. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT and Klibanski A. (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80: 1386-1392 [PMID:7714115]
  149. Moneta D, Richichi C, Aliprandi M, Dournaud P, Dutar P, Billard JM, Carlo AS, Viollet C, Hannon JP, Fehlmann D, Nunn C, Hoyer D, Epelbaum J and Vezzani A. (2002) Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur J Neurosci 16: 843-849 [PMID:12372020]
  150. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y and Melmed S. (2004) Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J. Clin. Invest. 114: 349-56 [PMID:15286801]
  151. Møller LN, Stidsen CE, Hartmann B and Holst JJ. (2003) Somatostatin receptors. Biochim. Biophys. Acta 1616: 1-84 [PMID:14507421]
  152. Najib S, Saint-Laurent N, Estève JP, Schulz S, Boutet-Robinet E, Fourmy D, Lättig J, Mollereau C, Pyronnet S and Susini C et al.. (2012) A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway. Mol. Cell. Biol. 32: 1004-16 [PMID:22203038]
  153. Naylor SL, Sakaguchi AY, Shen LP, Bell GI, Rutter WJ and Shows TB. (1983) Polymorphic human somatostatin gene is located on chromosome 3. Proc. Natl. Acad. Sci. U.S.A. 80: 2686-9 [PMID:6133281]
  154. Nunn C, Langenegger D, Hurth K, Schmidt K, Fehlmann D and Hoyer D. (2003) Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists. Eur. J. Pharmacol. 465: 211-8 [PMID:12681432]
  155. Nunn C, Rueping M, Langenegger D, Schuepbach E, Kimmerlin T, Micuch P, Hurth K, Seebach D and Hoyer D. (2003) Beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptide derivatives as potent agonists at somatostatin sst(4) receptors. Naunyn Schmiedebergs Arch. Pharmacol. 367: 95-103 [PMID:12595949]
  156. Nunn C, Schoeffter P, Langenegger D and Hoyer D. (2003) Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806. Naunyn Schmiedebergs Arch. Pharmacol. 367: 1-9 [PMID:12616335]
  157. O'Carroll AM, Lolait SJ, König M and Mahan LC. (1992) Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol. Pharmacol. 42: 939-46 [PMID:1362243]
  158. O'Carroll AM, Raynor K, Lolait SJ and Reisine T. (1994) Characterization of cloned human somatostatin receptor SSTR5. Mol. Pharmacol. 46: 291-8 [PMID:8078491]
  159. Panetta R, Greenwood MT, Warszynska A, Demchyshyn LL, Day R, Niznik HB, Srikant CB and Patel YC. (1994) Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol. Pharmacol. 45: 417-27 [PMID:7908405]
  160. Patel YC. (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20: 157-98 [PMID:10433861]
  161. Patel YC, Greenwood M, Kent G, Panetta R and Srikant CB. (1993) Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem. Biophys. Res. Commun. 192: 288-94 [PMID:8386508]
  162. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H and Srikant CB. (1995) The somatostatin receptor family. Life Sci. 57: 1249-65 [PMID:7674817]
  163. Patel YC and Srikant CB. (1994) Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 135: 2814-7 [PMID:7988476]
  164. Perez J, Viollet C, Doublier S, Videau C, Epelbaum J and Baud L. (2003) Somatostatin binds to murine macrophages through two distinct subsets of receptors. J. Neuroimmunol. 138: 38-44 [PMID:12742651]
  165. Petrich A, Mann A, Kliewer A, Nagel F, Strigli A, Märtens JC, Pöll F and Schulz S. (2013) Phosphorylation of threonine 333 regulates trafficking of the human sst5 somatostatin receptor. Mol. Endocrinol. 27: 671-82 [PMID:23418396]
  166. Pfeiffer M, Koch T, Schröder H, Klutzny M, Kirscht S, Kreienkamp HJ, Höllt V and Schulz S. (2001) Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem. 276: 14027-36 [PMID:11134004]
  167. Pierotti AR, Harmar AJ, Tannahill LA and Arbuthnott GW. (1985) Different patterns of molecular forms of somatostatin are released by the rat median eminence and hypothalamus. Neurosci. Lett. 57: 215-20 [PMID:2863791]
  168. Piqueras L and Martinez V. (2004) Role of somatostatin receptors on gastric acid secretion in wild-type and somatostatin receptor type 2 knockout mice. Naunyn Schmiedebergs Arch Pharmacol 370: 510-520 [PMID:15599710]
  169. Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S and Schulz S. (2008) Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J. Clin. Endocrinol. Metab. 93: 1203-10 [PMID:18198230]
  170. Plöckinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, Vajkoczy P, Jakob W, Saeger W and Schulz S et al.. (2012) DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur. J. Endocrinol. 166: 223-34 [PMID:22065857]
  171. Poitout L, Roubert P, Contour-Galcéra MO, Moinet C, Lannoy J, Pommier J, Plas P, Bigg D and Thurieau C. (2001) Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. J. Med. Chem. 44: 2990-3000 [PMID:11520208]
  172. Pola S, Cattaneo MG and Vicentini LM. (2003) Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity. J. Biol. Chem. 278: 40601-6 [PMID:12902325]
  173. Pradayrol L, Jörnvall H, Mutt V and Ribet A. (1980) N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Lett. 109: 55-8 [PMID:7353633]
  174. Ramírez JL, Grant M, Norman M, Wang XP, Moldovan S, de Mayo FJ, Brunicardi C and Kumar U. (2004) Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. Mol. Cell. Endocrinol. 221: 105-19 [PMID:15223137]
  175. Raynor K, Murphy WA, Coy DH, Taylor JE, Moreau JP, Yasuda K, Bell GI and Reisine T. (1993) Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol. Pharmacol. 43: 838-44 [PMID:8100350]
  176. Reardon DB, Dent P, Wood SL, Kong T and Sturgill TW. (1997) Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol. Endocrinol. 11: 1062-9 [PMID:9212054]
  177. Reardon DB, Wood SL, Brautigan DL, Bell GI, Dent P and Sturgill TW. (1996) Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Biochem. J. 314 ( Pt 2): 401-4 [PMID:8670047]
  178. Ren SG, Taylor J, Dong J, Yu R, Culler MD and Melmed S. (2003) Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J. Clin. Endocrinol. Metab. 88: 4239-45 [PMID:12970293]
  179. Rettenbacher M and Reubi JC. (2001) Localization and characterization of neuropeptide receptors in human colon. Naunyn Schmiedebergs Arch. Pharmacol. 364: 291-304 [PMID:11683516]
  180. Reubi JC. (1985) New specific radioligand for one subpopulation of brain somatostatin receptors. Life Sci. 36: 1829-36 [PMID:2859510]
  181. Reubi JC. (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24: 389-427 [PMID:12920149]
  182. Reubi JC, Cortès R, Maurer R, Probst A and Palacios JM. (1986) Distribution of somatostatin receptors in the human brain: an autoradiographic study. Neuroscience 18: 329-46 [PMID:2874525]
  183. Reubi JC, Eisenwiener KP, Rink H, Waser B and Mäcke HR. (2002) A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur. J. Pharmacol. 456: 45-9 [PMID:12450568]
  184. Reubi JC, Horisberger U and Laissue J. (1994) High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int. J. Cancer 56: 681-8 [PMID:8314345]
  185. Reubi JC, Horisberger U, Studer UE, Waser B and Laissue JA. (1993) Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J. Clin. Endocrinol. Metab. 77: 1323-8 [PMID:7915721]
  186. Reubi JC, Horisberger U, Waser B, Gebbers JO and Laissue J. (1992) Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 103: 1207-14 [PMID:1356871]
  187. Reubi JC, Kappeler A, Waser B, Schonbrunn A and Laissue J. (1998) Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J. Clin. Endocrinol. Metab. 83: 3746-9 [PMID:9768695]
  188. Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW and Schonbrunn A. (1999) Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts. J. Clin. Endocrinol. Metab. 84: 2942-50 [PMID:10443702]
  189. Reubi JC, Mazzucchelli L and Laissue JA. (1994) Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 106: 951-9 [PMID:8144000]
  190. Reubi JC, Perrin M, Rivier J and Vale W. (1982) High affinity binding sites for somatostatin to rat pituitary. Biochem. Biophys. Res. Commun. 105: 1538-45 [PMID:6125148]
  191. Reubi JC, Perrin MH, Rivier JE and Vale W. (1981) High affinity binding sites for a somatostatin-28 analog in rat brain. Life Sci. 28: 2191-8 [PMID:6114372]
  192. Reubi JC, Schaer JC, Wenger S, Hoeger C, Erchegyi J, Waser B and Rivier J. (2000) SST3-selective potent peptidic somatostatin receptor antagonists. Proc. Natl. Acad. Sci. U.S.A. 97: 13973-8 [PMID:11095748]
  193. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS and Mäcke HR. (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27: 273-82 [PMID:10774879]
  194. Reubi JC, Waser B, Cescato R, Gloor B, Stettler C and Christ E. (2010) Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J. Clin. Endocrinol. Metab. 95: 2343-50 [PMID:20228164]
  195. Reubi JC, Waser B, Horisberger U, Krenning E, Lamberts SW, Gebbers JO, Gersbach P and Laissue JA. (1993) In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 82: 2143-51 [PMID:8400264]
  196. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF and Bläker M et al.. (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27: 4656-63 [PMID:19704057]
  197. Rivier J, Erchegyi J, Hoeger C, Miller C, Low W, Wenger S, Waser B, Schaer JC and Reubi JC. (2003) Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. J. Med. Chem. 46: 5579-86 [PMID:14667212]
  198. Rivier JE, Hoeger C, Erchegyi J, Gulyas J, DeBoard R, Craig AG, Koerber SC, Wenger S, Waser B and Schaer JC et al.. (2001) Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). J. Med. Chem. 44: 2238-46 [PMID:11405660]
  199. Rivier JE, Kirby DA, Erchegyi J, Waser B, Eltschinger V, Cescato R and Reubi JC. (2005) Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem 48: 515-522 [PMID:15658865]
  200. Robas N, Mead E and Fidock M. (2003) MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J. Biol. Chem. 278: 44400-4 [PMID:12915402]
  201. Rochaix P, Delesque N, Estève JP, Saint-Laurent N, Voight JJ, Vaysse N, Susini C and Buscail L. (1999) Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum. Gene Ther. 10: 995-1008 [PMID:10223733]
  202. Rohrer L, Raulf F, Bruns C, Buettner R, Hofstaedter F and Schüle R. (1993) Cloning and characterization of a fourth human somatostatin receptor. Proc. Natl. Acad. Sci. U.S.A. 90: 4196-200 [PMID:8483934]
  203. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM and Foor F et al.. (1998) Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282: 737-40 [PMID:9784130]
  204. Roth A, Kreienkamp HJ, Meyerhof W and Richter D. (1997) Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization. J. Biol. Chem. 272: 23769-74 [PMID:9295322]
  205. Schindler M, Harrington KA, Humphrey PP and Emson PC. (1995) Cellular localisation and co-expression of somatostatin receptor messenger RNAs in the human brain. Brain Res. Mol. Brain Res. 34: 321-6 [PMID:8750836]
  206. Schindler M, Kidd EJ, Carruthers AM, Wyatt MA, Jarvie EM, Sellers LA, Feniuk W and Humphrey PP. (1998) Molecular cloning and functional characterization of a rat somatostatin sst2(b) receptor splice variant. Br. J. Pharmacol. 125: 209-17 [PMID:9776362]
  207. Schmid HA and Schoeffter P. (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80 Suppl 1: 47-50 [PMID:15477717]
  208. Schonbrunn A and Tashjian Jr H. (1978) Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J. Biol. Chem. 253: 6473-83 [PMID:210185]
  209. Schwabe W, Brennan MB and Hochgeschwender U. (1996) Isolation and characterization of the mouse (Mus musculus) somatostatin receptor type-4-encoding gene (mSSTR4). Gene 168: 233-5 [PMID:8654950]
  210. Sevarino KA, Felix R, Banks CM, Low MJ, Montminy MR, Mandel G and Goodman RH. (1987) Cell-specific processing of preprosomatostatin in cultured neuroendocrine cells. J. Biol. Chem. 262: 4987-93 [PMID:2881926]
  211. Shen LP, Pictet RL and Rutter WJ. (1982) Human somatostatin I: sequence of the cDNA. Proc. Natl. Acad. Sci. U.S.A. 79: 4575-9 [PMID:6126875]
  212. Shimon I, Rubinek T, Hadani M and Alhadef N. (2004) PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J. Endocrinol. Invest. 27: 721-7 [PMID:15636423]
  213. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD and Melmed S. (1997) Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Invest. 99: 789-98 [PMID:9045884]
  214. Siehler S and Hoyer D. (1999) Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity. Naunyn Schmiedebergs Arch. Pharmacol. 360: 522-32 [PMID:10598791]
  215. Siehler S and Hoyer D. (1999) Characterisation of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity. Naunyn Schmiedebergs Arch Pharmacol 360: 510-521 [PMID:10598790]
  216. Siehler S, Seuwen K and Hoyer D. (1999) Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn Schmiedebergs Arch. Pharmacol. 360: 488-99 [PMID:10598788]
  217. Siehler S, Seuwen K and Hoyer D. (1998) [125I]Tyr10-cortistatin14 labels all five somatostatin receptors. Naunyn Schmiedebergs Arch. Pharmacol. 357: 483-9 [PMID:9650799]
  218. Siehler S, Seuwen K and Hoyer D. (1998) [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur. J. Pharmacol. 348: 311-20 [PMID:9652348]
  219. Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Plöckinger U and Strowski MZ. (2007) Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J. Clin. Endocrinol. Metab. 92: 673-80 [PMID:17105845]
  220. Singh V, Grötzinger C, Nowak KW, Zacharias S, Göncz E, Pless G, Sauer IM, Eichhorn I, Pfeiffer-Guglielmi B and Hamprecht B et al.. (2007) Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition. Endocrinology 148: 3887-99 [PMID:17525126]
  221. Sotos-Prieto M, Guillén M, Guillem-Sáiz P, Portolés O and Corella D. (2010) The rs1466113 polymorphism in the somatostatin receptor 2 gene is associated with obesity and food intake in a Mediterranean population. Ann. Nutr. Metab. 57: 124-31 [PMID:20948194]
  222. Srikant CB and Patel YC. (1981) Somatostatin receptors: identification and characterization in rat brain membranes. Proc. Natl. Acad. Sci. U.S.A. 78: 3930-4 [PMID:6115385]
  223. Stengel A, Goebel M, Wang L, Rivier J, Kobelt P, Monnikes H and Tache Y. (2010) Selective central activation of somatostatin receptor 2 increases food intake, grooming behavior and rectal temperature in rats. J. Physiol. Pharmacol. 61: 399-407 [PMID:20814067]
  224. Sternini C, Wong H, Wu SV, de Giorgio R, Yang M, Reeve Jr J, Brecha NC and Walsh JH. (1997) Somatostatin 2A receptor is expressed by enteric neurons, and by interstitial cells of Cajal and enterochromaffin-like cells of the gastrointestinal tract. J. Comp. Neurol. 386: 396-408 [PMID:9303425]
  225. Strowski MZ and Blake AD. (2008) Function and expression of somatostatin receptors of the endocrine pancreas. Mol. Cell. Endocrinol. 286: 169-79 [PMID:18375050]
  226. Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, Szalkowski D, Gopal-Truter S, Fisher JK, Schaeffer JM and Blake AD et al.. (2003) Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol. Endocrinol. 17: 93-106 [PMID:12511609]
  227. Strowski MZ, Parmar RM, Blake AD and Schaeffer JM. (2000) Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141: 111-7 [PMID:10614629]
  228. Tagliati F, Zatelli MC, Bottoni A, Piccin D, Luchin A, Culler MD and Degli Uberti EC. (2006) Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. Endocrinology 147: 3530-8 [PMID:16601140]
  229. Tallent M, Liapakis G, O'Carroll AM, Lolait SJ, Dichter M and Reisine T. (1996) Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. Neuroscience 71: 1073-81 [PMID:8684611]
  230. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U and Stalla GK. (2006) Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 66: 1576-82 [PMID:16452215]
  231. Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret JJ, Souque A, Susini C, Cordelier P and Buscail L. (2008) Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology 149: 3137-47 [PMID:18325993]
  232. Tower-Gilchrist C, Lee E and Sztul E. (2011) Endosomal trafficking of the G protein-coupled receptor somatostatin receptor 3. Biochem. Biophys. Res. Commun. 413: 555-60 [PMID:21925142]
  233. Tsutsumi A, Takano H, Ichikawa K, Kobayashi S and Koike T. (1997) Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells. Cell. Immunol. 181: 44-9 [PMID:9344495]
  234. Tulipano G, Soldi D, Bagnasco M, Culler MD, Taylor JE, Cocchi D and Giustina A. (2002) Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143: 1218-1224 [PMID:11897676]
  235. Vanetti M, Kouba M, Wang X, Vogt G and Höllt V. (1992) Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett. 311: 290-4 [PMID:1397330]
  236. Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, Susini C and Buscail L. (2002) Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 62: 6124-31 [PMID:12414637]
  237. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C and Caron P. (2005) Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur. J. Endocrinol. 152: 757-67 [PMID:15879362]
  238. Viollet C, Bodenant C, Prunotto C, Roosterman D, Schaefer J, Meyerhof W, Epelbaum J, Vaudry H and Leroux P. (1997) Differential expression of multiple somatostatin receptors in the rat cerebellum during development. J. Neurochem. 68: 2263-72 [PMID:9166718]
  239. Viollet C, Vaillend C, Videau C, Bluet-Pajot MT, Ungerer A, L'Heritier A, Kopp C, Potier B, Billard J, Schaeffer J, Smith RG, Rohrer SP, Wilkinson H, Zheng H and Epelbaum J. (2000) Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur J Neurosci 12: 3761-3770 [PMID:11029646]
  240. Vockel M, Pollok S, Breitenbach U, Ridderbusch I, Kreienkamp HJ and Brandner JM. (2011) Somatostatin inhibits cell migration and reduces cell counts of human keratinocytes and delays epidermal wound healing in an ex vivo wound model. PLoS ONE 6: e19740 [PMID:21589940]
  241. Waser B, Tamma ML, Cescato R, Maecke HR and Reubi JC. (2009) Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J. Nucl. Med. 50: 936-41 [PMID:19443580]
  242. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I and Schwaiger M. (2002) Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur. J. Nucl. Med. Mol. Imaging 29: 28-38 [PMID:11807604]
  243. Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S and Reubi JC. (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur. J. Nucl. Med. Mol. Imaging 30: 1338-47 [PMID:12937948]
  244. Wilkinson GF, Feniuk W and Humphrey PP. (1997) Characterization of human recombinant somatostatin sst5 receptors mediating activation of phosphoinositide metabolism. Br. J. Pharmacol. 121: 91-6 [PMID:9146892]
  245. Woltering EA. (2003) Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother. Radiopharm. 18: 601-9 [PMID:14503956]
  246. Wängler C, Waser B, Alke A, Iovkova L, Buchholz HG, Niedermoser S, Jurkschat K, Fottner C, Bartenstein P and Schirrmacher R et al.. (2010) One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET). Bioconjug. Chem. 21: 2289-96 [PMID:21082773]
  247. Xu Y, Song J, Bruno JF and Berelowitz M. (1993) Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4. Biochem. Biophys. Res. Commun. 193: 648-52 [PMID:8512564]
  248. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H and Seino S et al.. (1993) Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem. Biophys. Res. Commun. 195: 844-52 [PMID:8373420]
  249. Yamada Y, Post SR, Wang K, Tager HS, Bell GI and Seino S. (1992) Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc. Natl. Acad. Sci. U.S.A. 89: 251-5 [PMID:1346068]
  250. Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell GI and Seino S. (1992) Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol. Endocrinol. 6: 2136-42 [PMID:1337145]
  251. Yamada Y, Stoffel M, Espinosa 3rd R, Xiang KS, Seino M, Seino S, Le Beau MM and Bell GI. (1993) Human somatostatin receptor genes: localization to human chromosomes 14, 17, and 22 and identification of simple tandem repeat polymorphisms. Genomics 15: 449-52 [PMID:8449518]
  252. Yang L, Berk SC, Rohrer SP, Mosley RT, Guo L, Underwood DJ, Arison BH, Birzin ET, Hayes EC and Mitra SW et al.. (1998) Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. U.S.A. 95: 10836-41 [PMID:9724791]
  253. Yang SK, Parkington HC, Epelbaum J, Keating DJ and Chen C. (2007) Somatostatin decreases voltage-gated Ca2+ currents in GH3 cells through activation of somatostatin receptor 2. Am. J. Physiol. Endocrinol. Metab. 292: E1863-70 [PMID:17327372]
  254. Yasuda K, Espinosa 3rd R, Davis EM, Le Beau MM and Bell GI. (1993) Human somatostatin receptor genes: localization of SSTR5 to human chromosome 20p11.2. Genomics 17: 785-6 [PMID:8244401]
  255. Yasuda K, Rens-Domiano S, Breder CD, Law SF, Saper CB, Reisine T and Bell GI. (1992) Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. J Biol Chem 267: 20422-20428 [PMID:1328199]
  256. Yeung M and Treit D. (2012) The anxiolytic effects of somatostatin following intra-septal and intra-amygdalar microinfusions are reversed by the selective sst2 antagonist PRL2903. Pharmacol. Biochem. Behav. 101: 88-92 [PMID:22210489]
  257. Zabel BU, Naylor SL, Sakaguchi AY, Bell GI and Shows TB. (1983) High-resolution chromosomal localization of human genes for amylase, proopiomelanocortin, somatostatin, and a DNA fragment (D3S1) by in situ hybridization. Proc. Natl. Acad. Sci. U.S.A. 80: 6932-6 [PMID:6196780]
  258. Zheng H, Bailey A, Jiang MH, Honda K, Chen HY, Trumbauer ME, Van der Ploeg LH, Schaeffer JM, Leng G and Smith RG. (1997) Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. Mol. Endocrinol. 11: 1709-17 [PMID:9328352]